The Tokyo-based company said in a recent statement that Hataphar, formally Ha Tay Pharmaceutical Jsc, was the second largest drug company in Vietnam last year and the deal would help it get a foothold in Southeast Asia as part of its international expansion.
Le Xuan Thang, CEO of Hataphar, told
VnExpress
that the company would issue an additional 528 million shares equivalent to a 20 percent stake at a price of VND370 billion ($16 million).
The Japanese company would buy the remaining 4.9 percent from existing shareholders, he added.
Hataphar plans to use the proceeds to build a VND135 trillion ($58.2 million) plant in Hoa Lac Hi-Tech Park in Hanoi. Construction is set to begin in the last quarter of next year.
It reported revenues of VND915 billion in the first half, up 1 percent year-on-year, while post-tax profits grew by 6 percent to VND52.5 billion.
- Mitsubishi buys 10 pct stake in Masan mining unit
- Masan to buy out Vinacafe
- State to auction entire stake in leading cooking oil firm
- South Korea's CJ CGV to sell stake in Vietnamese subsidiary
- Japan’s ENEOS Corp. raises holding stakes in Petrolimex to 9%
- Vietnam to divest 36-percent state stake in brewer Sabeco
- Binh Son Refining and Petrochemical JSC reports Q3 profits
- PV Gas to sell stake in gas trading firm
- Japan-based Eneos plans to acquire US$28-million stake of Vietnam Petrolimex
